Accepted Manuscript

Safety of coronary angiography and PCI via the radial vs. femoral route in patients on uninterrupted oral anticoagulation with Warfarin

Nevin C. Baker DO, Erik W. O'Connell DO, Wah Wah Htun MD, Haiyan Sun MS, Sandy M. Green MD, Kimberly A. Skelding MD, James C. Blankenship MD, Thomas D. Scott DO, Peter B. Berger MD

PII: S0002-8703(14)00400-1 DOI: doi: 10.1016/j.ahj.2014.06.016

Reference: YMHJ 4662

To appear in: American Heart Journal

Received date: 12 March 2014 Accepted date: 28 June 2014



Please cite this article as: Baker Nevin C., O'Connell Erik W., Htun Wah Wah, Sun Haiyan, Green Sandy M., Skelding Kimberly A., Blankenship James C., Scott Thomas D., Berger Peter B., Safety of coronary angiography and PCI via the radial vs. femoral route in patients on uninterrupted oral anticoagulation with Warfarin, *American Heart Journal* (2014), doi: 10.1016/j.ahj.2014.06.016

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Section: Clinical Investigations

Safety of Coronary Angiography and PCI via the Radial vs. Femoral Route in Patients on Uninterrupted Oral Anticoagulation with Warfarin

Brief title: Radial Access on Warfarin

Nevin C. Baker, DO¹, Erik W. O'Connell, DO², Wah Wah Htun, MD¹, Haiyan Sun, MS³, Sandy M. Green, MD¹, Kimberly A. Skelding, MD¹, James C. Blankenship, MD¹, Thomas D. Scott, DO¹ and Peter B. Berger, MD^{1,4}

¹Department of Cardiology, ²Department of General Internal Medicine, ³Center for Health Research and ⁴Cardiovascular Center for Clinical Research, Geisinger Medical

Center, Danville, PA

Address for Correspondence:

Peter B. Berger, MD

Geisinger Clinic

M.C. 27-75

100 North Academy Avenue Danville, PA 17822

Tel: (570) 214-5057

Fax: (570) 214-1480

E-mail: pbberger@geisinger.edu

Financial support: No funding

Disclosures: Dr. Peter Berger has served as a consultant to Medicure and Janssen (each for less than \$10,000) and has received research funding for Geisinger Clinic for studies on which he is the Principal Investigator from AstraZeneca, The Medicines Company, BMS, Sanofi, Lilly/DS (all for more than \$10,000). None of the other authors report any potential conflicts.

Word count (abstract): 293

Word count (total): (inclusive of title page, abstract, tables, references): 5,397

Download English Version:

https://daneshyari.com/en/article/5928474

Download Persian Version:

https://daneshyari.com/article/5928474

<u>Daneshyari.com</u>